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NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
(NST) FOR LYMPHOID MALIGNANCIES USING PENTOSTATIN/LOW-
DOSE TOTAL BODY IRRADIATION
Bociek, G.R.1, Pavletic, S.Z.2, Foran, J.3, Rubocki, R.J.1, Kuszynski,
C.A.1, Lynch, J.C.1, Bierman, P.J.1, Vose, J.M.1, Armitage, J.O.1,
Joshi, S.S.1, Talmadge, J.E.1, Enke, C.A.1, Wisecarver, J.L.1,
McGuire, T.R.1 1. University of Nebraska Medical Center, Omaha,
NE; 2. National Cancer Institute/National Institutes of Health, Be-
thesda, MD; 3. University of Alabama, Birmingham, AB
Between 9/01 and 8/03 13 patients with relapsed/refractory lym-
phoid malignancies have undergone NST. The median age at
transplantation was 52 years (range 21-63). The median number of
prior therapies was 5 (range 1-7). Diseases transplanted repre-
sented a broad variety of lymphoid malignancies including
Hodgkin’s disease (n 3) and non-Hodgkin’s lymphoma (n 10).
The conditioning regimen consisted of Pentostatin 4 mg/m2/day
IV on days -21, -20, and -19, followed by low dose total body
irradiation on day –1. Graft-versus-host disease (GVHD) prophy-
laxis consisted of cyclosporine/mycophenolate mofetil. Stem cell
transplantation was from matched related (n  5) or matched
unrelated (n  8) donors. All toxicities were minimal. At day 28
the median values for donor chimerism were 90% (range 55%-
100%) for CD3 cells and 95% (range 50%-100%) for WBC. At
day 70 the respective median values were 95% (range 50%-
100%) and 100% (range 80%-100%) respectively. Sustained en-
graftment has been observed in all cases to date and no patients
have required donor leukocytes. Acute GVHD has been seen in
6/13 patients, and chronic GVHD in 6/8 evaluable patients. Treat-
ment related mortality is 15% (one death from intracranial hem-
orrhage, one death from chronic GVHD). With a median fol-
low-up for surviving patients of 11.2 months, the event-free
survival and overall survival are presently projected at 73%. Of six
patients who underwent autologous stem cell transplantation as
their immediate prior therapy (excluding salvage therapy prior to
NST), ﬁve have had remission durations which have exceeded their
prior remission duration with autologous transplantation (P 0.07
by logrank). An additional patient with Waldenstrom’s macroglob-
ulinemia had evidence of minimal residual disease (persistent mar-
row disease and an elevated IgM) for six months post transplant,
and with no further therapy at one year post transplant has a
normal marrow and IgM levels. The use of Pentostatin/TBI as a
preparative regimen for NST in patients with refractory/relapsed
lymphoid malignancies is associated with minimal toxicity, sus-
tained engraftment, and an acceptable treatment related mortality
given the patient population. The observation that a number of
patients have had remission inversions (compared with immedi-
ately prior high-dose chemotherapy/autologous stem cell trans-
plantation) and the occurrence of a late remission in the absence of
other therapy offers indirect evidence of a graft-versus-lymphoma
effect.
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LONG TERM DISEASE FREE SURVIVAL IN PATIENTS WITH MANTLE
CELL LYMPHOMA FOLLOWING HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Ganti, A.K., Bierman, P.J., Lynch, J.C., Bociek, R.G., Vose, J.M.,
Armitage, J.O. University of Nebraska Medical Center, Omaha, NE
Mantle cell lymphoma (MCL) is a B-cell lymphoma with tumor
cells that are typically CD5 and CD23- and overexpress cyclin
D1. The response rate and overall survival in patients with MCL
are signiﬁcantly lower than other types of lymphoma. No chemo-
therapeutic regimen has been proven to be consistently curative for
MCL. The role of hematopoietic stem cell transplantation
(HSCT) in the treatment of MCL is unclear. Also it is not known
which type of transplantation is more effective. Hence we studied
the clinical course of the disease in patients who received autolo-
gous or allogeneic HSCT for MCL to determine if the type of
transplant had an effect on the clinical outcome. Ninety seven
patients who received HSCT for MCL were studied, including 80
patients who received an autologous HSCT and 17 patients who
received an allogeneic HSCT from a matched sibling donor. None
of the allogeneic transplants employed a reduced intensity prepar-
ative regimen. Primary end points were response at day 100,
mortality at day 100, relapse rate (RR), event free survival (EFS)
and overall survival (OS). Patients who received an autologous
HSCT were older (median age: 56 yrs vs. 47 yrs) (p  0.01) and
were less likely to receive conditioning with total body irradiation
(9% vs. 94%) (p  0.0001). There was no signiﬁcant difference in
the complete response rate at day 100 between patients receiving
autologous and allogeneic HSCT (73% vs. 62%). Mortality at day
100 was higher among recipients of allogeneic HSCT (19%) as
compared to autologous HSCT (0%) (p  0.01). The estimated
5-yr RR was 21% among patients receiving an allogeneic HSCT
compared to 56% for those receiving an autologous HSCT (p 
0.11). The estimated 5-yr EFS was 44% for allogeneic HSCT and
39% for autologous HSCT (p 0.85). The estimated 5-yr OS was
49% for allogeneic HSCT and 47% for autologous HSCT (p 
0.51). Ten patients (8 autologous HSCT, 2 allogeneic HSCT)
received HyperCVAD (hyperfractionated cyclophosphamide, vin-
cristine, doxorubicin and dexamethasone) prior to transplant and
there have not been any relapses or deaths amongst these patients
at a median follow-up of 16 months. In conclusion, allogeneic
HSCT patients tended to have a lower relapse rate, although this
difference was not statistically signiﬁcant. However the OS and
EFS were similar in both groups. Both types of transplants can lead
to long-term disease-free survival in approximately 40% patients
with MCL especially after chemotherapy with HyperCVAD.
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A PHASE I/II STUDY OF XCELLERATED T CELLS AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS
WITH MULTIPLE MYELOMA
Martin, T.1, Vij, R.2, Vescio, R.3, Borrello, I.4, Siegel, D.5, Bashey, A.6,
DiPersio, J.2, Berenson, J.7, Ferrand, C.8, Janmohamed, F.9, Yuan, V.9,
Bouchard, L.9, Hami, L.9, Berenson, R.J.9, Bonyhadi, M.9, Frohlich,
M.W.9 1. University of California, San Francisco, CA; 2. Washington
University, St. Louis, MO; 3. Cedars Sinai Medical Center, Los Angeles,
CA; 4. Johns Hopkins University, Baltimore, MD; 5. Hackensack Uni-
versity, Hackensack, NJ; 6. University of California, San Diego, CA; 7.
Institute for Myeloma and Bone Cancer Research, Los Angeles, CA; 8.
Etablissment Francais du Sang, Besancon, France; 9. Xcyte Therapies,
Inc., Seattle, WA
Previous studies in multiple myeloma have demonstrated a sig-
niﬁcant association between survival and lymphocyte recovery fol-
lowing autologous transplantation (Porrata et al., Blood 2001). Fur-
thermore, in a murine model of myeloma, adoptive transfer of
activated T cells following bone marrow transplantation has dem-
onstrated a marked anti-tumor effect in vivo (Hou Fowler, BBMT
2003). We have initiated a clinical trial in patients with multiple
myeloma to evaluate the activity of T cells activated and expanded
ex vivo with the Xcellerate™ Process, which uses anti-CD3 and
anti-CD28 antibodies covalently linked to magnetic beads
(Xcyte™ Dynabeads®). Following induction therapy, patients un-
dergo a leukapheresis to collect peripheral blood mononuclear cells
for the Xcellerate Process. Patients then undergo stem cell mobi-
lization and collection, followed by high dose chemotherapy with
melphalan (200 mg/m2). Three days following peripheral blood
stem cell infusion, patients receive an infusion of 5-10  1010
autologous Xcellerated T Cells. Thirty-one of the planned 35
patients have been treated to date. T cells have been successfully
activated and expanded in all patients. In the ﬁrst 18 patients, T
cells expanded 166  44 fold (mean  SD), with the ﬁnal product
being 99.0  0.1% CD3. A bioreactor process was subse-
quently instituted, and T Cells expanded 253  86 fold, with ﬁnal
product 98.0 3.2% CD3 (n 10). Xcellerated T Cell infusions
have been well-tolerated, with no Grade 3 or 4 acute infusional
toxicities. Lymphocyte recovery has been rapid, with counts reach-
ing 500/mm3 generally within 1-2 days following T cell infusion
(Day 4-5 post transplant). Historically, lymphocyte recovery to
500/mm3 usually does not occur for 3 or more weeks post-
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transplant in myeloma patients treated with this regimen, but
without Xcellerated T Cells. The T cell receptor repertoire of
leukapheresis samples as measured by V	 spectratyping demon-
strates marked skewing. Following the Xcellerate Process, the
repertoire returns to a more normal pattern (n  5; p  0.01). In
addition, the T cell repertoire measured 25 days following T cell
infusion (Day 28 posttransplant) demonstrates a more normal
pattern than prior to T cell infusion (n  5). This is in marked
contrast to the severe skewing of T cell receptor diversity normally
seen in myeloma patients following autologous stem cell transplan-
tation (Mariani et al, BJH 2001). Data on clinical outcomes will be
presented.
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LONG TERM OUTCOME FOLLOWING AUTOLOGOUS AND ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR
LYMPHOMA
Deshpande, A.T., Bociek, G.R., Bierman, P.J., Vose, J.M., Lynch, J.C.,
Armitage, J.O. University of Nebraska Medical center, Omaha, NE
Follicular lymphoma (FL) accounts for approximately 25-35% of
all cases of non-Hodgkin’s Lymphoma (NHL). Autologous
(ASCT) and allogeneic (alloSCT) hematopoietic stem cell trans-
plantation can induce prolonged remissions in patients with FL,
and studies of alloSCT demonstrate very low relapse rates and
evidence of a plateau on event-free survival (EFS) curves, suggest-
ing the possibility that some patients may be cured with this
modality. We present the long-term outcome in 204 patients with
FL treated with ASCT (n  186) or alloSCT (n  18) between
04/83 and 05/98. For ASCT and alloSCT groups respectively the
median age was 45 vs. 39 years and the median time from diagnosis
to transplant 27 vs 24 months. The majority of patients in both
groups had follicular grade 2 histology, and the conditioning reg-
imen was cyclophosphamide/total body irradiation (Cy/TBI) in
54% of ASCT and 72% of alloSCT. The median follow-up of
surviving patients is 7.8 years (range 1.7 to 19.2 years). Patients
who received an alloSCT had a superior ﬁve-year EFS (76% vs.
41%; p  0.034), but not overall survival (OS) (76% vs. 61%; p 
0.18). To control for the possible confounding effect of preparative
regimen we performed a limited analysis of all patients undergoing
transplantation with Cy/TBI, and found that patients undergoing
alloSCT had superior EFS (p  0.034) and a trend toward im-
proved OS (p  0.18) compared with ASCT. Multivariate analysis
of patients undergoing ASCT demonstrated an inferior EFS in
patients who received 3 prior chemotherapies (hazard ratio [HR]
 3.5; 95% conﬁdence interval [CI]  1.8-7.0, p  0.001) and in
patients 60 years of age (HR  4.7; 95% CI  1.6-13.8, p 
0.001). Variables predicting for an increased risk of death in ASCT
included3 prior chemotherapies (HR 5.0; 95% CI 2.4-10.6,
p 0.0001), age60 years (HR 9.2; 95% CI 2.8-30, p 0.001),
female gender (HR  2.4; 95% CI  1.2-4.9, p  0.013), and the
presence of resistant disease (HR  4.9; 95% CI  1.8-13.6, p 
0.01). In conclusion, this data offers some evidence that with
adequate follow-up alloSCT leads to superior EFS compared with
ASCT, but because of morbidity/mortality associated with al-
loSCT OS is similar in both groups. Notwithstanding issues of
selection bias, the observation that these differences are not ac-
counted for by the intensity of the preparative regimen suggests
that a lack of tumor contamination, an allogeneic graft-versus-
lymphoma effect, or both may be responsible for the improved
outcome.
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THE CITY OF HOPE EXPERIENCE WITH NOVEL TRANSPLANT REGI-
MENS THAT INCORPORATE STANDARD AND ESCALATED DOSE 90YT-
TRIUM IBRITUMOMAB TIUXETAN (90Y-ZEVALIN) RADIOIMMUNO-
THERAPY (RIT) FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) IN PATIENTS WITH B-CELL NON-HODGKIN’S LYMPHOMA
(NHL): TARGETED INTENSIFICATION WITHOUT INCREASED TOXICITY
AND ELIMINATION OF TOTAL BODY IRRADIATION (TBI)
Nademanee, A.1, Fung, H.1, Molina, A.2, Krishnan, A.1, Rodriguez,
R.1, Popplewell, L.1, Spielberger, R.T.1, O’Donnell, M.1, Snyder, D.1,
Parker, P.1, Stein, A.1, Kogut, N.1, Falk, P.1, Sahebi, F.1, Zain, J.1,
Saville, W.2, Raubitschek, A.1, Forman, S.J.1 1. City of Hope Cancer
Center (COH), Duarte, CA; 2. IDEC Pharmaceuticals Corporation,
San Diego, CA
Background: 90Y-Zevalin was the 1st FDA-approved RIT for
treatment of pts with relapsed or refractory CD20 low-grade,
follicular, or transformed B-cell NHL, including rituximab-refrac-
tory NHL. Two COH clinical trials are currently investigating
whether standard (0.4 mCi/kg) or escalated doses of 90Y-Zevalin
can be combined safely with myeloablative regimens for ASCT.
Methods/Results: 1) A dose escalation study of 90Y-Zevalin with
dosimetric guidance (maximum radiation dose to the liver of 1000
cGy)  high-dose VP-16  cyclophosphamide (CY) has accrued
26 pts who are evaluable for efﬁcacy and safety. Median age was 49
(25-58). Median dose of 90Y-Zevalin delivered was 71 mCi (37-105
mCi). All pts with measurable disease achieved remission, except
one pt had a positive PET scan. 4 pts received IF-XRT to sites of
prior bulky disease. Median day to ANC 1,000 was 10 days
(8-17). Median days to platelet count 50, 000 was 20 (12-123).
With a median follow-up of 20 months (range 1-40), 21 pts (81%)
are alive and in remission. 2) The standard-dose study of 90Y-
Zevalin (0.4 mCi/kg)  high-dose BEAM has accrued 12 pts,
primarily over the age of 60. Dosimetry was not performed. Me-
dian age was 61 (56-78). All pts engrafted promptly after ASCT
and there were no transplant-related deaths. The median total dose
of 90Y-Zevalin was 32 mCi (range: 20.7-40). Because stem cell
support was used, a maximum 40 mCi dose of Zevalin was allowed.
With a median follow-up of 9 months (range, 4-16), 2 pts have
relapsed, and one of these died from progressive disease. The
remaining 10 pts (83%) are well without evidence of NHL. Con-
clusions: Results from the dose escalation study suggest that high-
dose 90Y-Zevalin can be safely administered with high-dose VP-
16/CY; that high-dose 90Y-Zevalin can be used in place of TBI
without the need for a lead-shielded isolation room; and that this
new high-dose combination is effective in heavily pre-treated pts
with poor-risk NHL. Results from the second study indicate that
the combination of conventional-dose 90Y-Zevalin  high-dose
BEAM is a well-tolerated and easily administrated ASCT regimen
for older pts with aggressive CD20 NHL and does not require
dosimetry. These preliminary results taken in aggregate suggest
that incorporation of 90Y-Zevalin into novel SCT regimens pro-
vides a targeted intensiﬁcation of the transplant regimen and po-
tentially increased anti-tumor activity without added toxicity.
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ZEVALIN DOSE-ESCALATION FOLLOWED BY HIGH-DOSE BEAM AND
AUTOTRANSPLANT IN CD20 RELAPSED OR REFRACTORY NON-
HODGKIN LYMPHOMA (NHL)
Winter, J.N.1, Inwards, D.2, Erwin, W.3, Wiseman, G.2, Rademaker,
A.1, Patton, D.R.1, Williams, S.1, Tallman, M.S.1, Mehta, J.1, Sin-
ghal, S.1, Micallef, I.2, Multani, P.4, Zimmer, M.1, Spies, S.1, Molina,
A.4, White, C.4, Gordon, L.I.1 1. Feinberg School of Medicine, North-
western University, Chicago, IL; 2. Mayo Clinic College of Medicine,
Rochester, MN; 3. MD Anderson Cancer Center, Houston, TX; 4.
IDEC Pharmaceuticals, San Diego, CA
90Y Zevalin was added to high-dose BEAM followed by auto-
transplant in 22 patients with relapsed or refractory CD20 NHL
with the goal of increasing progression-free and overall survival
(PFS, OS). Cohorts of 3-6 patients were treated at doses calculated
to result in increasing radiation exposure(100, 300, 500, 700 cGy)
to the critical organ (liver, lung or kidney). On D -22, rituximab(R)
250 mg/m2 was administered followed by the imaging dose of 111In
Zevalin (5 mCi). Imaging was performed immediately and at 4, 24,
72, and 144 hours post-injection; dosimetry was performed on D
-15. On D -14, R at 250 mg/m2 was administered followed by 90Y
Zevalin at a dose calculated to deliver the cohort-prescribed ab-
sorbed radiation dose to the critical organ. On D -6 through -1,
patients received BEAM. On D 0, a minimum of 2.0  106
CD34 cells/kg was infused and G-CSF 5 g/kg SQ daily was
begun. The median age was 53 (range: 25-72). 5 patients had
mantle cell lymphoma, 9 had diffuse aggressive NHL, 4 had low
grade NHL, and 4 had transformed NHL. The majority (55%)
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